# Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/developing-targeted-therapies-in-low-frequency-molecular-subsets-of-a-disease/becd1349-aa73-4de3-83cd-a43abfb0f98c

> FDA guidance document: Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease. Issue date: October 16, 2018. Get complete insights and analysis.

---

## Details

- Title: Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2018-10-16
- Last Changed: 2024-04-09
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2017-D-6617">FDA-2017-D-6617</a>

## Related Documents

- [Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-for-industry/a65eb174-50f7-4cfb-a751-33c206aaa385)
- [Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-for-treatment-guidance-for-industry/a2b09b4f-527f-406f-a71d-c6e62d4737ad)
- [Migraine: Developing Drugs for Acute Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/migraine-developing-drugs-for-acute-treatment/39ba4b4b-6c93-4849-a087-866c6bf4edff)